Incretin-based Drugs Market Forecast Report 2025-2034 Featuring AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, GSK, Lupin, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda, Viatris - ResearchAndMarkets.com

The "Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.

The Incretin-based Drugs Market was valued at USD 37.4 billion in 2024, and is projected to reach USD 68.7 billion by 2034, rising at a CAGR of 6.3%.

The market is categorized by drug type into GLP-1 receptor agonists and DPP-4 inhibitors, with a market size of USD 35.5 billion in 2023. The rising demand for GLP-1 receptor agonists is driven by their ability to enhance insulin secretion and suppress glucagon levels, effectively managing blood sugar. These drugs also promote weight loss by controlling appetite and slowing digestion, making them a preferred option for diabetes patients. Extended-release formulations, such as once-weekly injections, improve patient adherence and expand market reach.

The market is also segmented by the route of administration into oral and injectable drugs. The oral segment accounted for USD 28.7 billion in 2024, with a market share of 76.8%. Oral formulations offer a convenient alternative to injections, leading to higher patient compliance. Continuous research efforts have led to improved efficacy and safety profiles, making oral medications increasingly preferred. These formulations are easy to distribute, store, and administer, reducing the burden on healthcare providers and enhancing accessibility across various healthcare settings.

By indication, the market includes type 2 diabetes mellitus, obesity and weight management, and other metabolic disorders. The type 2 diabetes mellitus segment held the largest share, generating USD 26.6 billion in revenue in 2024. The rising global incidence of type 2 diabetes, attributed to poor dietary habits and lifestyle factors, fuels the demand for incretin-based drugs. These medications effectively lower blood sugar levels while reducing the risk of hypoglycemia, offering a safer treatment option for aging populations and those prone to severe blood sugar fluctuations.

The distribution channel segment comprises hospital pharmacies, retail pharmacies, and e-commerce. Hospital pharmacies led the market with USD 19.2 billion in revenue in 2024. These settings ensure secure access to medications, particularly for newly diagnosed patients or those requiring specialized care. Pharmacists provide guidance on dosage, side effects, and formulation differences, enhancing treatment adherence. Comprehensive support services, including medication management programs and close monitoring of treatment responses, further contribute to market growth.

North America dominated the market, accounting for USD 17.1 billion in 2024, with the U.S. leading at USD 15.5 billion. The rising prevalence of diabetes, cardiovascular diseases, and obesity continues to drive demand for incretin-based drugs. Supportive regulatory frameworks and rapid advancements in drug development contribute to the region's market expansion.

Comprehensive Market Analysis and Forecast

• Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
• Competitive landscape with Porter's Five Forces and PESTEL analysis
• Market size, segmentation, and regional forecasts
• In-depth company profiles, business strategies, financial insights, and SWOT analysis

Companies Featured

• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly and Company
• GlaxoSmithKline
• Lupin Limited
• Merck
• Novo Nordisk
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company
• Viatris

Key Attributes:

Report Attribute	Details
No. of Pages	120
Forecast Period	2024 - 2034
Estimated Market Value (USD) in 2024	$37.4 Billion
Forecasted Market Value (USD) by 2034	$68.7 Billion
Compound Annual Growth Rate	6.3%
Regions Covered	Global

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

2.1 Industry 360 Synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising prevalence of type 2 diabetes mellitus

3.2.1.2 Shift toward non-insulin therapies

3.2.1.3 Advancements in drug delivery technologies

3.2.1.4 Cardiovascular and weight management benefits

3.2.2 Industry pitfalls and challenges

3.2.2.1 High treatment costs

3.2.2.2 Adverse effects and contraindications

3.3 Growth potential analysis

3.4 Regulatory landscape

3.5 Gap analysis

3.6 Pipeline analysis

3.7 Porter's analysis

3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction

4.2 Company market share analysis

4.3 Competitive analysis of major market players

4.4 Competitive positioning matrix

4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, by Drug Type, 2021-2034 ($ Mn)

5.1 Key trends

5.2 GLP-1 receptor agonists

5.3 DPP-4 inhibitors

Chapter 6 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Mn)

6.1 Key trends

6.2 Oral

6.3 Injectable

Chapter 7 Market Estimates and Forecast, by Indication, 2021-2034 ($ Mn)

7.1 Key trends

7.2 Type 2 diabetes mellitus

7.3 Obesity and weight management

7.4 Other metabolic disorders

Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)

8.1 Key trends

8.2 Hospital pharmacies

8.3 Retail pharmacies

8.4 E-commerce

Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)

9.1 Key trends

9.2 North America

9.2.1 U.S.

9.2.2 Canada

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Spain

9.3.5 Italy

9.3.6 Netherlands

9.4 Asia-Pacific

9.4.1 China

9.4.2 Japan

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

9.6.3 UAE

Chapter 10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/nygpby

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250423635572/en/